How often pharmaceutical companies actually perform postmarketing trials (phase IV) are contained in a report from Cutting Edge Information, an industry intelligence firm. The top 20 pharmaceutical companies initiate phase IV trials for 87% of new products, while 92% of mid-sized companies will perform the postmarketing studies. Small companies conduct the trials only 69% of the time. The report, entitled Phase IV Clinical Trials: Post-Marketing Study Management Structure, Strategy, and Benchmarks, is available on-line at www.postmarketingtrials.com. It includes clinical trial performance measures such as cycle times, resource-based measures, and efficiency or operational metricssuch as patient retention rates and data errors. Average per-patient clinical trial costs by therapeutic area are also included in the new report.